An Engineered IGF2 Mutant for Lysosomal Targeting Chimeras Development and Membrane Proteins Degradation
Y. Pan, Q. Xiang, K. Deng, M. Anwar, L. Wang, Y. Wang, Q. Liang, L. Shen, J. Yang, W. Shen
This paper introduces eiLYTACs, an engineered IGF2-based technology that degrades membrane proteins and inhibits tumor growth by avoiding IGF1R activation.
bioRxiv · Feb 20, 2024 · PreprintBiochemistry